eFFECTOR Debuts as Publicly Traded Next-Generation Oncology Company

eFFECTOR Therapeutics, a clinical-stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero and Cellular and Molecular Pharmacologist Kevan Shokat, today completed its business combination with Locust Walk Acquisition Corp. eFFECTOR Therapeutics expects its common stock and public warrants will commence trading on Nasdaq under the new trading symbols “EFTR” and “EFTRW”, respectively, starting on August 26, 2021.